Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This resea…

Liver CancerRhabdomyosarcomaMalignant Rhabdoid Tumor+3 more

~Estimated

~$10 – $6,250

Baylor College of MedicineNCT04715191

Phase 1

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different way…

HepatoblastomaHepatocellular CarcinomaWilms Tumor+5 more

~Estimated

~$10 – $6,250

Baylor College of MedicineNCT06198296

Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) mali…

Solid Tumor (Excluding CNS)Liver Cell CarcinomaMalignant Rhabdoid Tumor+7 more

~Estimated

~$10 – $6,250

Seattle Children's HospitalNCT07148050